GE Plans to Invest US$156 Million in a Biopharmaceutical Manufacturing Campus in Cork, Ireland

Introduction:

GE plans to invest US$156 million(€150 million) in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland’s strategic site at Lough beg, Ringaskiddy, Co. Cork.

Features:

The manufacturing campus will feature KUBio™, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers.

Nearly 500 new jobs are expected to rise through E BioPark and 400 with bio-Pharma companies and a further 100 employed directly by GE. This project would also create up to 800 construction jobs.

The construction of this project is expected to begin by mid- 2017.

The project will include four fully-equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE running centralised shared utilities and site services. The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

KUBioenables pharmaceutical companies to quickly deploy new biologics manufacturing capacity and bring medicines to market faster. KUBios increase manufacturing flexibility and are between 25 and 50 percent more cost-effective to build than comparable traditional facilities. Carbon dioxide emissions can be reduced by 75 percent and water and energy use by approximately 80 percent. Build time can be shortened to 18 months from the usual 3 years.

GE is also making plans with the National Institute for Bioprocessing Research and Training (NIBRT) to create a NIBRT-GE Single-use Centre of Excellence at NIBRT’s Dublin facility. Approximately 1, 500 bioprocessing professionals are expected to be trained annually on next-generation biologic manufacturing technologies.

Specifications:

Name GE
Location Cork, Ireland
Type Biopharmaceutical Manufacturing Campus
Estimated Cost US$156 Million
Schedule Expected to begin by mid- 2017
Parties Involved GE Healthcare
IDA Ireland
NIBRT

TOP